![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/10\/20261021_FZR1_ALL_Technology_and_Modalities-768x922.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Chinese academic consortium<\/p>\n Event Type<\/strong><\/p>\n Peer-Reviewed Preclinical Publication (Cell Death & Disease)<\/p>\n Modality<\/strong><\/p>\n Synthetic-lethal biomarker strategy; ATR kinase inhibition (ceralasertib); APC\/C inhibition (proTAME)<\/p>\n Asset<\/strong><\/p>\n Not applicable (biomarker and mechanism hypothesis)<\/p>\n Target<\/strong><\/p>\n ATR; FZR1 (APC\/C activator)<\/p>\n Disease Area<\/strong><\/p>\n Relapsed or refractory acute lymphoblastic leukemia<\/p>\n A peer-reviewed online-first study identifies FZR1 deficiency as a candidate biomarker for sensitivity to ATR inhibition in relapsed or refractory acute lymphoblastic leukemia. The result connects a defined cell-cycle defect to a pharmacologic synthetic-lethal mechanism, with no clinical validation yet.<\/p>\n The authors combined a focused CRISPR screen using ceralasertib with mechanistic experiments in ALL cell lines, primary cells and in-vivo models. FZR1 deficiency increased ATR-inhibitor sensitivity. Mechanistically, SKP2 increased while p21\/p27 fell, accelerating entry into S phase; ATR inhibition then removed later checkpoints, increased DNA damage and induced mitotic catastrophe. Pharmacologic APC\/C inhibition with proTAME also synergized with ceralasertib. The accepted, citable Cell Death & Disease article was published online 21 October 2026, ahead of final copyediting.<\/p>\n This is more than another DNA-damage response association: FZR1 provides an experimentally testable route to stratify a biologically heterogeneous relapsed ALL population. An available ATR inhibitor supports a feasible translational path, but the clinically relevant prevalence and clonality of FZR1 loss in children and adults are not established here.<\/p>\n An alternative is that FZR1-low status marks broad replication stress rather than a specific, exploitable dependency. ATR inhibitors can suppress normal proliferating marrow, and dual APC\/C-ATR suppression may narrow the therapeutic index further. Prospective assays must distinguish pathogenic FZR1 loss from low expression caused by sample composition, and test leukemic versus normal progenitor selectivity, PK\/PD and resistance escape in patient-derived disease.<\/p>\n FZR1 activates the APC\/C ubiquitin ligase to regulate cell-cycle transitions. ATR kinase coordinates responses to replication stress. ALL is a lymphoid leukemia for which relapsed disease can resist standard chemotherapy and immune therapies.<\/p>\n Inference: FZR1 is an attractive biomarker hypothesis for ATR programs, but clinical development should begin with prevalence, assay and therapeutic-window work rather than efficacy claims.<\/p>\n Signal Importance: 4 of 5. Signal Direction: Positive, preclinical. Confidence in Facts: High. Confidence in Interpretation: Moderate\u2013Low. The direction score describes the evidence at this stage. It does not imply clinical approval, treatment readiness or commercial outcome.<\/p>\n","protected":false},"excerpt":{"rendered":" A peer-reviewed online-first study identifies FZR1 deficiency as a candidate biomarker for sensitivity to ATR inhibition in relapsed or refractory acute lymphoblastic leukemia. The result connects a defined cell-cycle defect to a pharmacologic synthetic-lethal…<\/p>\n","protected":false},"author":1,"featured_media":3825,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1076,1140,1142,1139,1141],"class_list":["post-3813","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-acute-lymphoblastic-leukemia","tag-atr-inhibitor","tag-ceralasertib","tag-fzr1","tag-synthetic-lethality"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3813"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3813\/revisions"}],"predecessor-version":[{"id":3832,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3813\/revisions\/3832"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3825"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n